Emerging paradigms of treating diabetic nephropathy

Affiliations

¹ Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA 92868, USA.
² Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA, USA.
³ Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA 92868, USA; Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA, USA. Electronic address: kkz@uci.edu.

Free article

Comment

Yongen Chang et al. Lancet Diabetes Endocrinol. 2018 Dec.

Free article

. 2018 Dec;6(12):912-913.

doi: 10.1016/S2213-8587(18)30304-8. Epub 2018 Nov 6.

¹ Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA 92868, USA.
² Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA, USA.
³ Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA 92868, USA; Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA, USA. Electronic address: kkz@uci.edu.

No abstract available

Comment on

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. de Zeeuw D, et al. Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6. Lancet Diabetes Endocrinol. 2018. PMID: 30413396 Clinical Trial.